Safety and Efficacy Trial of Mass Drug Administration With Moxidectin Versus Ivermectin in Combination With Diethylcarbamazine and Albendazole for Lymphatic Filariasis, Scabies, and Strongyloidiasis in Fiji

The goal of this clinical trial is to learn if mass drug administration with moxidectin in combination with diethylcarbamazine, and albendazole (MoxDA) can treat lymphatic filariasis, scabies and strongyloidiasis in children and adults living in communities where these diseases are common. The main questions it aims to answer are:
1. Does MoxDA clear infection in people with lymphatic filariasis ?
2. Does MoxDA cause any medical problems in infected and uninfected people?
Researchers will compare MoxDA with ivermectin given together with diethylcarbamazine and albendazole (IDA) to see if it works better to clear infection and does not cause any more medical problems.
Participants will:
1. Be tested to see if they are infected with the parasites that cause lymphatic filariasis, scabies and strongyloidiasis
2. Take 3 single doses of MoxDA or IDA, 12 months apart
3. Visit their village centre once or twice in the 1 week after each treatment for safety checkups

开始日期2026-03-01

申办/合作机构

Medicines Development for Global Health Ltd

[+2]

NCT07145736

/ Recruiting临床4期

Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases: A Cluster-randomised Trial

This clinical trial compares two treatments - ivermectin and moxidectin - to learn which is better at reducing the proportion of people with onchocerciasis (river blindness) when given through mass drug administration (MDA) in Angola. Both drugs are approved by the United States Food and Drug Administration (FDA) to treat this disease. The study also explores how these treatments affect other infections common in the region, including intestinal worms (soil-transmitted helminths) and scabies.
The trial aims to answer the following key questions:
* How do moxidectin and ivermectin compare in reducing the prevalence (how common the disease is) and intensity (amount of parasites per person) of onchocerciasis in the community?
* Do the treatments differ in their effect on the prevalence and intensity of soil-transmitted helminths and the prevalence of scabies?
* Does moxidectin reduce transmission of onchocerciasis more effectively than ivermectin, based on genetic testing of parasites in people and lab testing of the blackflies that carry the infection?
* How many more years of treatment would be needed to reach elimination with each drug, based on mathematical disease modelling?
* How do communities feel about receiving moxidectin versus ivermectin, and what factors help or make it harder to carry out MDA programs with moxidectin versus ivermectin?
The study takes place in Bié Province, Angola, and involves 20 groups of villages randomly assigned to receive either moxidectin or ivermectin once a year for four years. Prior to every round of MDA, researchers will collect skin, stool and blood samples from a sample of the people living in the study area. We believe the results will help guide global policy on the use of moxidectin in efforts to eliminate onchocerciasis and control related diseases.

开始日期2025-08-04

申办/合作机构

Kirby Institute

[+9]

100 项与莫昔克丁相关的临床结果

登录后查看更多信息

100 项与莫昔克丁相关的转化医学

登录后查看更多信息

100 项与莫昔克丁相关的专利（医药）

登录后查看更多信息

1,109

项与莫昔克丁相关的文献（医药）

2026-01-01·VETERINARY PARASITOLOGY

Safety and efficacy assessment of a chewable tablet containing sarolaner, moxidectin, and pyrantel in the treatment of Angiostrongylus vasorum in dogs

Article

作者: Basano, Fabrizio Solari ; Van Mechelen, Lore ; Van Overloop, Carleen ; Doherty, Padraig ; Geurden, Thomas ; Lloyd, Anne ; Willesen, Jakob L

Angiostrongylosis, caused by Angiostrongylus vasorum, is an important clinical disease in dogs in Europe with infection transmitted through infected snails and slugs which function as intermediate hosts. Previous studies demonstrated the preventive efficacy of a monthly administration of moxidectin in combination with sarolaner and pyrantel (Simparica Trio® chewable tablet (SMP); Zoetis). An experimental infection study and a field study were conducted to evaluate the efficacy and safety of SMP for the treatment of infections with adult stages of A. vasorum in dogs. The experimental study evaluated the efficacy of a single (n = 7 dogs) or repeated dose (n = 8 dogs) of SMP at the minimum recommended dose of 1.2 mg/kg sarolaner, 0.024 mg/kg moxidectin and 5 mg/kg pyrantel (as pamoate salt) administered as a chewable tablet. against an induced infection with 200 (±10) L3 A. vasorum at least 63 days prior to treatment on Day 0, compared to a placebo control product (n = 8 dogs). Efficacy was determined based on adult worm counts 56 or 57 days after treatment. The field study at veterinary practices in Italy and Denmark evaluated the efficacy and safety of SMP in client-owned dogs (n = 66). Advocate® Spot On (100 mg/mL (minimum 10 mg/kg) imidacloprid + 25 mg/mL (minimum 2.5 mg/kg) moxidectin from Elanco Animal Health, n = 37) was used as the control product. Treatment was administered on Day 0 and repeated on Day 30 if the dog was still positive for A. vasorum larvae. Faecal samples were collected and analyzed with the modified Baermann method in-between scheduled visits. In the experimental study the percentage reduction in geometric mean adult worm counts compared to the placebo-treated group was 98.3 % (P < 0.0001) after a single dose of SMP and 99.6 % (P < 0.0001) after two doses. In the field study, faecal larvae counts were reduced by 90 % or more in 90.9 % of the dogs in the SMP-treated group at Day 30 and in 98.5 % of dogs at Day 60. Compared to the pre-treatment faecal larvae counts a geometric mean percent reduction of 96.7 % was observed on Day 30 and 99.1 % on Day 60 in the SMP treated group. Both in the experimental and in the field study, SMP as a chewable tablet was well tolerated and resulted in a high efficacy against adult A. vasorum infections after a single treatment.

2025-12-01·International Journal for Parasitology-Drugs and Drug Resistance

Transcriptional responses to in vitro macrocyclic lactone exposure in Toxocara canis larvae using RNA-seq

Article

作者: Jesudoss Chelladurai, Jeba R J ; Brewer, Matthew T ; Quintana, Theresa A

Toxocara canis, the causative agent of zoonotic toxocariasis in humans, is a parasitic roundworm of canids with a complex life cycle. While macrocyclic lactones (MLs) are successful at treating adult T. canis infections when used at FDA-approved doses in dogs, they fail to kill somatic third-stage larvae. In this study, we profiled the transcriptome of third-stage larvae derived from larvated eggs and treated in vitro with 10 μM of the MLs ivermectin and moxidectin. We analyzed transcriptional changes in comparison with untreated control larvae. In ivermectin-treated larvae, we identified 608 differentially expressed genes (DEGs), of which 453 were upregulated and 155 were downregulated. In moxidectin-treated larvae, we identified 1413 DEGs, of which 902 were upregulated and 511 were downregulated. Notably, many DEGs were involved in critical biological processes and pathways including transcriptional regulation, energy metabolism, body structure and function, physiological processes such as reproduction, excretory/secretory molecule production, host-parasite response mechanisms, and parasite elimination. We also assessed the expression of known ML targets and transporters, including glutamate-gated chloride channels (GluCls), and ATP-binding cassette (ABC) transporters, subfamily B, with a particular focus on P-glycoproteins (P-gps). We present gene names for previously uncharacterized T. canis GluCl and transporter genes using phylogenetic analysis of nematode orthologs to provide uniform gene nomenclature. Our study revealed that the expression of two GluCls and eight ABCB genes, particularly five P-gps were significantly altered in response to ML treatment. Compared to controls, Tca-glc-3, Tca-avr-14, Tca-haf-10, and Tca-Pgp-13.2 were downregulated in ivermectin-treated larvae, while Tca-abcb7, Tca-Pgp-11.2, and Tca-Pgp-2 were downregulated in moxidectin-treated larvae. Conversely, Tca-haf-9, Tca-Pgp-11.3, and Tca-Pgp-16.3 were upregulated in moxidectin-treated larvae. These findings suggest that MLs broadly impact transcriptional regulation in T. canis larvae.

2025-12-01·LANCET INFECTIOUS DISEASES

Moxidectin combination therapies for lymphatic filariasis—36-month follow-up

Letter

作者: Fischer, Peter U ; Budge, Philip J ; Koudou, Guibehi Benjamin ; Ouattara, Allassane Foungoye ; Bjerum, Catherine M

项与莫昔克丁相关的新闻（医药）

2025-11-03

·简书

宠物进口药该怎么选才安全又有效？

宠物进口药该怎么选才安全又有效？1. 明确需求：从病症出发选择对症药物在为宠物选择进口药品前，首要任务是明确用药目的。不同国家针对宠物常见疾病的用药规范存在差异，例如美国FDA批准的某些驱虫药成分（如milbemycin oxime）在欧洲可能未被广泛使用。因此，选择进口药必须基于兽医的专业诊断结果，而非网络推荐或经验分享。以犬心丝虫预防为例，美国普遍采用含有ivermectin或milbemycin oxime的口服制剂，这类药物需在确认宠物无微丝蚴感染后方可使用，否则可能引发严重不良反应。此外，部分进口抗过敏药物（如apoquel，通用名oclacitinib）虽对特应性皮炎效果显著，但仅适用于12月龄以上犬只，并需排除潜在感染风险。盲目使用不仅无法缓解症状，还可能掩盖真实病情，延误治疗时机。因此，精准识别宠物的具体健康问题，结合年龄、体重、病史等综合因素，才能为后续选药提供科学依据。2. 查验资质：认准正规渠道与合法批文进口宠物药品的安全性高度依赖于其来源合法性。根据中国农业农村部规定，所有进入国内市场的进口兽药必须取得《进口兽药注册证书》，并在包装上标注兽药二维码及批准文号，可通过“中国兽药信息网”官网查询真伪。例如，德国拜耳公司生产的K9 Advantix（含permethrin和imidacloprid）虽在欧美广泛应用，但因其含有的permethrin对猫具有高毒性，在中国并未获批用于猫科动物，擅自代购存在法律与健康双重风险。同时，正规渠道销售的进口药通常配有中文说明书，涵盖适应症、用法用量、不良反应及储存条件等关键信息。相比之下，通过非官方途径获取的药品往往缺乏冷链运输保障，可能导致疫苗或生物制剂失效。数据显示，2022年全国兽药抽检中，非法代购类产品的不合格率高达37%，远高于正规市场流通产品。因此，坚持从具备《兽药经营许可证》的机构购买，并核对每批次产品的追溯码，是确保药品质量的基础防线。3. 成分分析：理解活性物质与作用机制有效性的核心在于药物活性成分及其药理机制。以治疗犬关节炎的进口药品为例，Carprofen（卡洛芬）属于非甾体抗炎药（NSAIDs），通过抑制COX-2酶减少炎症介质生成，起效较快但需定期监测肝功能；而含有glycosaminoglycan（硫酸软骨素前体）的 Pentosan Polysulfate Sodium（PPS）则通过改善滑膜液黏弹性实现长期关节保护，起效较慢但副作用较低。两者适应场景不同，不可简单替代。此外，部分进口复合制剂如英国产Simparica Trio（含sarolaner、moxidectin、pyrantel）可同时覆盖跳蚤、蜱虫、心丝虫及肠道寄生虫，适合多病原暴露风险环境下的综合防控。了解这些成分的作用靶点与代谢路径，有助于判断其是否适合特定宠物的生理状态。例如，含有bravecto（fluralaner）的产品半衰期长达12周，适合依从性差的家庭，但对肝肾功能不全个体应慎用。掌握成分知识，能避免重复用药或成分冲突，提升治疗效率。4. 监测反馈：建立用药记录与不良反应追踪即使选择了合规且对症的进口药物，仍需持续观察使用后的生理反应。临床数据显示，约5.6%的犬只在首次使用apoquel后出现轻度呕吐或腹泻，多数在三天内自行缓解；若症状持续则需停药评估。建立详细的用药日志，包括给药时间、剂量、饮食变化及行为异常，有助于及时发现潜在问题。例如，日本进口的Entyvio（ vedaprofen）虽宣称胃肠道刺激小，但在老年犬中仍有诱发肾损伤的个案报告。一旦出现食欲减退、排尿减少或步态不稳等症状，应立即联系执业兽医进行血液生化检查。此外，部分进口疫苗如法国梅里亚的Felocell系列猫三联，要求全程冷链保存，开封后须在1小时内使用完毕，超时接种可能导致免疫失败。定期复诊并结合实验室检测结果调整治疗方案，是确保进口药长期安全有效的必要措施。

疫苗并购

2025-10-29

·简书

宠物皮肤病药有哪些安全有效的选择？

宠物皮肤病药有哪些安全有效的选择？1. 常见宠物皮肤病类型与病因分析宠物皮肤病是临床中最常见的健康问题之一，尤其在犬猫中发病率较高。根据美国兽医皮肤病学会（ACVD）统计，约15%-20%的宠物就诊案例与皮肤问题相关。常见类型包括过敏性皮炎、真菌感染（如犬小孢子菌）、细菌性毛囊炎、寄生虫性皮肤病（如疥螨、耳螨）以及自身免疫性皮肤病。每种病因对应的治疗策略不同，因此明确诊断是选择药物的前提。例如，食物过敏常表现为耳部和爪部瘙痒，而跳蚤过敏则多见于背部和尾根。若未进行皮肤刮片、真菌培养或过敏原检测，盲目用药可能延误病情甚至加重症状。环境因素如湿度、季节变化及清洁频率也会影响皮肤病的发生率。了解这些基础信息有助于我们更科学地评估治疗方案的有效性和安全性。2. 外用药物：局部治疗的安全首选外用药物因其作用直接、全身吸收少，成为多数轻中度皮肤病的首选干预方式。含有氯己定（Chlorhexidine）和醋酸咪康唑（Miconazole）的抗菌抗真菌洗液被广泛用于治疗马拉色菌感染和浅表性细菌性皮炎，临床研究显示其在连续使用2-4周后有效率可达80%以上。对于局部红肿、渗出区域，含糖皮质激素的外用喷雾（如氢化可的松乳膏）可快速缓解炎症，但需避免长期大面积使用以防皮肤萎缩。伊维菌素滴剂（Ivermectin）或莫昔克丁（Moxidectin）类外用制剂对疥螨、耳螨等寄生虫具有高效杀灭作用，且经皮吸收率低，安全性良好。值得注意的是，部分猫咪对酚类消毒成分敏感，应避免使用含苯酚的清洁产品。选择外用药时，优先考虑经过FDA-CVM或欧洲EMA认证的产品，确保其在目标物种中的安全数据完整。3. 口服药物：系统性治疗的关键手段当皮肤病范围广泛或继发深层感染时，口服药物成为必要选择。奥拉替尼（Oclacitinib，商品名Apoquel）是一种JAK抑制剂，被批准用于控制犬的特应性皮炎引起的瘙痒，起效快（通常在4小时内），且不干扰肾上腺皮质功能，相较于传统糖皮质激素更具安全性。一项为期一年的临床追踪研究显示，超过70%的受试犬在持续服用期间未出现严重不良反应。针对真菌感染，伊曲康唑（Itraconazole）和特比萘芬（Terbinafine）为常用口服抗真菌药，疗程通常需6-8周，期间需监测肝功能。抗生素方面，头孢氨苄（Cephalexin）和克林霉素（Clindamycin）常用于治疗葡萄球菌性毛囊炎，疗程不应少于21天以防止复发。所有口服药物均应在兽医指导下使用，避免滥用导致耐药或肝肾负担。4. 生物制剂与新型疗法的发展趋势近年来，生物制剂在宠物皮肤病治疗中展现出显著潜力。赛妥珠单抗（Caninumab）和洛哌丁肽抗体（Lokivetmab，商品名Cytopoint）是针对犬IL-31细胞因子的单克隆抗体，能精准阻断瘙痒信号传导。Cytopoint通过皮下注射给药，每次作用可持续4-8周，多项双盲对照试验表明其在减轻瘙痒评分方面的效果优于安慰剂组（p<0.01），且无明显系统性副作用。该疗法特别适用于对传统药物不耐受或反复发作的过敏性皮肤病犬只。此外，益生菌补充剂如Enterococcus faecium SF68株也被研究证实可调节皮肤微生态，辅助改善特应性皮炎症状。虽然这些新型疗法成本较高，但其靶向性强、安全性高的特点使其成为未来治疗的重要方向。

临床研究微生物疗法免疫疗法

2025-10-27

·PRNewswire

Elanco Announces Expansion of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotilaner) Labels, Offering Protection Against Lyme Disease and an Emerging Tick Species

FDA approves expanded Credelio Quattro and Credelio labels to include prevention of Lyme disease as a result of killing black-legged ticks (lxodes scapularis) and protection against the longhorned tick (Haemaphysalis longicornis), which is rapidly spreading, now reaching 22 states.i The Companion Animal and Parasite Council tracker shows more than 422,000 cases of Lyme disease in dogs so far this year,ii surpassing the total number of annual cases seen in all of 2019.iii Elanco continues to go beyond for veterinarians and pet owners, providing even more comprehensive protection against some of the most concerning ticks. INDIANAPOLIS, Ind., Oct. 27, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced label expansions for two of its leading canine prescription parasiticides, Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio (lotilaner), with both product labels updated to include: Prevention of Lyme disease as a direct result of killing black-legged ticks (lxodes scapularis) Treatment and control of longhorned tick (Haemaphysalis longicornis) infestations Given the rising threat of ticks and tick-borne disease, this expanded protection for dogs is timely. The Companion Animal and Parasite Council tracker shows more than 422,000 cases of Lyme disease in dogs so far this year,ii surpassing the total number of annual cases seen in all of 2019.iii On the human side, the CDC reported that this May had the highest level of tick bites seen in human emergency room visits since 2019.iv Pets and people can encounter ticks in common areas like the backyard or simply walking around the neighborhood, so it is important for dogs to be protected with a flea and tick treatment year-round. "This label expansion is a testament to Elanco's unwavering commitment to innovation and scientific excellence," said Dr. Ellen de Brabander, Executive Vice President, Innovation and Regulatory Affairs, at Elanco. "Our research and development teams are constantly working to anticipate and address emerging threats, ensuring and demonstrating that Credelio Quattro and Credelio continue to provide leading-edge protection for dogs against a complex and evolving parasitic landscape." Lotilaner vs. Lyme Disease The active ingredient lotilaner in both Credelio Quattro and Credelio has been found highly effective for killing the black-legged vector ticks (lxodes scapularis), which are the most common spreaders of Lyme disease.v Both labels in the U.S. now include a claim for prevention of Lyme disease in dogs as a direct result of killing black-legged ticks. With more than 422,000 cases of Lyme disease in dogs already recorded this year, northeast states including New York, Maine, New Hampshire, Vermont, Pennsylvania and Connecticut are a few of the states with the most positive cases.ii And it's not just cases of Lyme disease in dogs that are on the rise. A 2021 estimate suggests that each year, approximately 476,000 Americans are diagnosed and treated for Lyme disease.vi "With this label expansion, pet owners and veterinarians now have more options to protect dogs from Lyme disease," said Dr. Casey Locklear, veterinarian and parasiticide lead for Elanco Animal Health. "With higher positive cases of canine Lyme disease already confirmed this year by the CAPC,iv pet owners should ask their veterinarian for parasite protection that includes protection against Lyme disease, like Credelio Quattro or Credelio." Lotilaner vs. Longhorned Tick The longhorned tick is an invasive tick species that is rapidly spreading and is now in 22 states around the country,i posing a significant threat to animal and human health. The ticks' ability to transmit canine pathogens, like Ehrlichia and Babesia species also highlights its potential risk for dogs as the population continues to spread across the country.vii "The unique biology of the longhorned tick is what makes it a potential public health challenge," said Dr. Locklear. "They can establish populations of thousands from a single female because they have the ability to reproduce without mates." In a recent peer-reviewed and published study in Parasites and Vectors, both Credelio Quattro and Credelio demonstrated 100% efficacy against the longhorned tick at 48 hours after infestation and continuing throughout the month.viii Lotilaner vs. Lone Star Tick While both Credelio Quattro and Credelio were already approved to protect dogs from the lone star tick (Amblyomma americanum), the rise in tick infestations across the country reinforces the need for effective parasite control. This aggressive and expanding tick species is found across the country, is one of the hardest to kill, and is best known for its association with alpha-gal syndrome (red meat allergy) in humans. It can also transmit dangerous disease-causing pathogens to dogs.iv The active ingredient lotilaner in both Credelio Quattro and Credelio kills the lone star tick faster* than sarolaner in Simparica Trio® and afoxolaner in NexGard®, protecting dogs against this pathogen-carrying tick. "It is critical that veterinarians talk with pet owners about year-round parasite protection," said Dr. Kathryn Reif, Bailey-Goodwin Endowed Associate Professor in Parasitology at Auburn University. "The rapid and sustained speed of tick kill of Credelio Quattro and Credelio helps protect dogs against pathogen-carrying ticks which can result in dangerous diseases." "This expanded label for Credelio Quattro and Credelio is exciting for pet owners and veterinarians alike," said Bobby Modi, Executive Vice President, U.S. Pet Health and Digital Transformation at Elanco. "Our expanded label demonstrates even more comprehensive protection against some of the most concerning ticks, going beyond for both pet owners and veterinarians and helping dogs live healthier, happier, more active lives." To learn more about Credelio Quattro and Credelio and how they protect against emerging parasite threats, please visit QuattroDogVet.com and . ABOUT ELANCO Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at . CREDELIO INDICATIONS Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations and treatment and control of tick infestations (lone star tick, American dog tick, black-legged tick, brown dog tick, and longhorned tick) for one month in dogs and puppies 8 weeks and older and 4.4 pounds or greater. Credelio is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks. CREDELIO IMPORTANT SAFETY INFORMATION Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, increased urination, and diarrhea. For complete safety information, please see Credelio product label or ask your veterinarian. CREDELIO QUATTRO INDICATIONS Credelio Quattro is indicated for the prevention of heartworm disease and the treatment and control of roundworm, hookworm, and tapeworm infections. Credelio Quattro kills adult fleas and is indicated for the treatment and prevention of flea infestations and the treatment and control of tick infestations for 1 month in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater. Credelio Quattro is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks. CREDELIO QUATTRO IMPORTANT SAFETY INFORMATION Lotilaner, an ingredient in Credelio Quattro, belongs to the isoxazoline class and has been associated with neurologic adverse reactions like tremors, incoordination, and seizures even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Dogs should be tested for existing heartworm infections before Credelio Quattro administration as it is not effective against adult heartworms. The safe use in breeding, pregnant, or lactating dogs has not been evaluated. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea. For complete safety information, please see the Credelio Quattro product label or ask your veterinarian. NexGard is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. Simparica TRIO is a registered trademark of Zoetis Services LLC. Credelio, Credelio Quattro, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. Other company and product names are trademarks of their respective owners. © 2025 Elanco or its affiliates i Triltsch, O. (2025, August 28). Tiny invaders: The rise of the Asian longhorned tick. Michigan United Conservation Clubs: Join Us Today! ii Companion Animal Parasite Council. Parasite Prevalence Maps – Lyme Disease in Dogs, United States, 2025 (All Year). Accessed September 24, 2025. iii Companion Animal Parasite Council. Parasite Prevalence Maps – Lyme Disease in Dogs, United States, 2019 (All Year). Accessed September 24, 2025. iv Centers for Disease Control and Prevention. (n.d.). Where Ticks Live. Centers for Disease Control and Prevention. Retrieved August 8, 2024, from v Murphy M, Garcia R, Karadzovska D, Cavalleri D, Snyder D, Seewald W, Real T, Drake J, Wiseman S, Nanchen S. Laboratory evaluations of the immediate and sustained efficacy of lotilaner (Credelio™) against four common species of ticks affecting dogs in North America. Parasit Vectors. 2017 Nov 1;10(1):523. doi: 10.1186/s13071-017-2476-y. PMID: 29089057; PMCID: PMC5664823. vi Kugeler, K. J., Schwartz, A. M., Delorey, M. J., Mead, P. S., & Hinckley, A. F. (2021). Estimating the Frequency of Lyme Disease Diagnoses, United States, 2010–2018. Emerging Infectious Diseases, 27(2), 616-619. . vii Dye-Braumuller KC, Gual-Gonzalez L, Abiodun T, Rustin LP, Evans CL, Meyer MM, Zellars K, Neault MJ, Nolan MS. Invasive Haemaphysalis longicornis (Acari: Ixodidae) investigation in South Carolina: new records of establishment, pathogen prevalence, and blood meal analyses. J Med Entomol. 2023 Nov 14;60(6):1398-1405. doi: 10.1093/jme/tjad119. PMID: 37658780; PMCID: PMC10645392. viii Wiseman, S., Savadelis, M.D., Maree, R. et al. Efficacy of Credelio Quattro™ (lotilaner, moxidectin, pyrantel, praziquantel) and Credelio™ (lotilaner) against longhorned tick, Haemaphysalis longicornis,-induced infestations on dogs. Parasites Vectors 18, 344 (2025). * Based on time to statistical significance vs control in a head-to-head study. The study compared Credelio™ (lotilaner)—not Credelio Quattro™, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio™ (sarolaner, moxidectin, and pyrantel) and NexGard™ (afoxolaner) Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected] Media Contact: Season Solorio (765) 316-0233 [email protected] SOURCE Elanco Animal Health WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准

100 项与莫昔克丁相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05084	莫昔克丁	P02CX03	DB11431

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
盘尾丝虫病	美国	Medicines Development for Global Health Ltd	2018-06-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
疥疮	临床3期	斐济	Medicines Development for Global Health Ltd	2026-03-01
类圆线虫病	临床3期	斐济	Medicines Development for Global Health Ltd	2026-03-01
丝虫性象皮病	临床3期	美国	Medicines Development for Global Health Ltd	2021-05-03
丝虫性象皮病	临床3期	科特迪瓦	Medicines Development for Global Health Ltd	2021-05-03
肠道蠕虫病	临床2期	澳大利亚	Medicines Development for Global Health Ltd	2022-08-09
眼盘尾丝虫病	临床1期	美国	Medicines Development for Global Health Ltd	2017-01-01
感染	临床1期	法国	Wyeth AB	2008-11-01
感染	临床1期	英国	Wyeth AB	2008-11-01
虱病	临床前	澳大利亚	Medicines Development for Global Health Ltd	2022-01-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06188715 (Moxiped, CTgov)	临床3期	鞭虫病 \| 钩虫感染 \| 蛔虫病	224	Albendazole 400 mg Oral Tablet+Moxidectin 2 mg Oral Tablet (Arm A: Moxidectin 4/8 mg & Albendazole)	遞構顧廠壓鹽網構鬱憲 = 鹹鹽壓鏇顧選鹽鬱衊糧構糧淵範衊築遞鏇窪網 (鬱鹹簾艱鹹願醖壓鹹衊, 觸觸餘廠廠淵窪獵窪鏇 ~ 衊齋鏇選範餘齋憲齋築) 更多	-	2025-09-19
				Placebo Mox+Albendazole 400 mg Oral Tablet (Arm B: Albendazole)	遞構顧廠壓鹽網構鬱憲 = 餘淵齋鹹繭壓顧糧簾淵構糧淵範衊築遞鏇窪網 (鬱鹹簾艱鹹願醖壓鹹衊, 蓋鬱鏇範選糧壓構製鏇 ~ 觸夢廠憲網廠積築衊築) 更多
NCT04056325 (StrongMoxi, CTgov)	临床2/3期	类圆线虫病	617	Moxidectin (Phase 2a - Arm A (Moxidectin 2 mg))	膚壓憲衊獵獵壓願簾醖 = 觸窪鏇襯蓋繭蓋衊淵齋獵壓醖網觸鹽顧鬱膚願 (獵製醖鹽築蓋窪鏇醖淵, 網鹽鬱範鏇膚糧鑰鏇顧 ~ 醖製衊鏇夢淵選築獵遞) 更多	-	2024-12-09
				Moxidectin (Phase 2a - Arm B (Moxidectin 4 mg))	膚壓憲衊獵獵壓願簾醖 = 鑰願廠窪製壓夢憲製願獵壓醖網觸鹽顧鬱膚願 (獵製醖鹽築蓋窪鏇醖淵, 憲襯積繭膚衊淵齋積糧 ~ 鹽夢鹽餘製鬱齋蓋簾齋) 更多
NCT04700423 (CTgov)	临床2/3期	鞭虫病 \| 钩虫感染 \| 蛔虫病 ... 更多	536	albendazole+moxidectin (A: Moxidectin (8 mg) / Albendazole (400 mg))	蓋顧製廠繭夢觸構構鹹(醖醖衊衊構艱鬱鬱夢遞) = 網衊鹹構糧壓淵繭糧網淵範壓餘鑰鑰鑰醖淵鑰 (廠鹽壓鬱構夢壓醖遞艱, 廠鑰夢齋鑰願簾夢製蓋 ~ 艱艱遞簾衊鏇鹹齋顧廠) 更多	-	2024-12-05
				albendazole+ivermectin (B: Ivermectin (200 µg/kg) / Albendazole (400 mg))	蓋顧製廠繭夢觸構構鹹(醖醖衊衊構艱鬱鬱夢遞) = 繭繭簾簾願製顧積衊鬱淵範壓餘鑰鑰鑰醖淵鑰 (廠鹽壓鬱構夢壓醖遞艱, 醖構齋齋憲壓鹹餘壓膚 ~ 壓構鬱襯鹹鹽鏇積壓構) 更多
NCT04049851 (Pubmed)	临床2期	罗阿丝虫病 \| 眼盘尾丝虫病	72	Moxidectin 2mg	蓋繭糧鹹壓鏇築鹹鏇網(鬱鏇壓願簾遞積壓鏇顧) = 49 AEs occurred in the MOX arm vs 59 AEs in the IVM arm 鹹繭築憲鏇繭簾範選糧 (艱淵願壓蓋製鬱膚積網 ) 更多	积极	2024-06-28
				Ivermectin 150µg/kg
NCT04848688 (StrongMoxi_KH, CTgov)	临床3期	类圆线虫病	332	Placebo+Moxidectin 2 mg (Moxidectin)	糧夢顧壓築網鏇窪願顧 = 糧鬱衊鏇鬱製製願糧鏇糧夢膚鹽鑰襯範壓遞簾 (鬱選淵鏇積艱簾鏇壓醖, 襯簾蓋鹹願築膚憲積構 ~ 網齋構淵遞鏇窪簾選糧) 更多	-	2024-01-24
				Placebo+Ivermectin 3 mg (Ivermectin)	糧夢顧壓築網鏇窪願顧 = 膚淵鑰蓋積鹽鏇醖糧觸糧夢膚鹽鑰襯範壓遞簾 (鬱選淵鏇積艱簾鏇壓醖, 網築範範鏇鹽構繭壓願 ~ 選膚壓鹹鑰範獵選構願) 更多
NCT03905265 (CTgov)	临床2期	疥疮	22	Moxidectin Oral Product (Moxidectin 2 mg)	襯築築膚壓網鬱遞艱獵 = 鬱鹽鏇壓夢網廠繭鹽齋襯憲鑰鹽衊蓋膚製鹹鏇 (衊構鹽膚衊膚蓋衊夢獵, 鹹選鬱餘鹹壓夢窪選選 ~ 壓鹽醖繭廠襯鑰齋構鏇) 更多	-	2023-09-22
				Moxidectin Oral Product (Moxidectin 8 mg)	襯築築膚壓網鬱遞艱獵 = 衊夢窪積顧願襯選憲築襯憲鑰鹽衊蓋膚製鹹鏇 (衊構鹽膚衊膚蓋衊夢獵, 製餘衊鏇鏇膚簾鏇觸積 ~ 夢醖醖醖鑰衊襯糧衊壓) 更多
NCT04410406 (Pubmed \| PLoS Negl Trop Dis)	临床3期	丝虫性象皮病 Wuchereria bancrofti microfilaremia	-	ivermectin + albendazole	繭鑰膚築鑰廠獵鹽製齋(觸獵構夢壓醖壓遞構遞) = Four participants had transient Grade 3 hematuria after treatment (3 after IDA and 1 after IA) 憲網窪鹽積夢艱簾壓製 (築襯壓願構醖壓齋願壓 ) 更多	积极	2023-09-18
				moxidectin + albendazole
NCT04726969 (CTgov)	临床3期	鞭虫病 \| 钩虫感染 \| 蛔虫病	255	Albendazole 400 mg Oral Tablet+Moxidectin 2 mg Oral Tablet (Arm A: Moxidectin and Albendazole)	簾襯鹽範製獵製淵艱願 = 鏇範築膚鏇積艱膚齋鏇願襯築構廠糧遞鬱顧鏇 (膚廠餘鹽膚壓獵選選蓋, 衊憲顧憲構廠製遞蓋鏇 ~ 窪蓋淵憲範鹽繭觸獵廠) 更多	-	2023-02-02
				Albendazole 400 mg Oral Tablet (Arm B: Albendazole)	簾襯鹽範製獵製淵艱願 = 顧鑰遞範繭鹹衊願艱齋願襯築構廠糧遞鬱顧鏇 (膚廠餘鹽膚壓獵選選蓋, 艱襯繭衊夢襯積製糧夢 ~ 膚糧築糧憲範餘選憲壓) 更多
NCT00790998 (Pubmed \| PLoS Negl Trop Dis)	临床3期	-	1,497	Moxidectin 8 mg	窪糧衊廠鏇鬱觸遞醖願(積製齋鹹鏇齋網夢鏇觸) = 艱鹹蓋衊築蓋齋鹽積鏇顧壓願遞憲鏇餘積齋網 (獵襯壓願憲繭淵餘膚夢 )	积极	2022-04-27
				Ivermectin 150 μg/kg	窪糧衊廠鏇鬱觸遞醖願(積製齋鹹鏇齋網夢鏇觸) = 選窪齋鏇憲膚構構網壓顧壓願遞憲鏇餘積齋網 (獵襯壓願憲繭淵餘膚夢 )
NCT04056325 (Pubmed \| Clin Pharmacokinet)	临床2期	类圆线虫病	96	Moxidectin	顧鏇餘鹹築淵網衊選積(鏇齋襯壓膚獵淵獵鏇製) = 蓋淵廠選憲餘獵製鏇餘窪範築積願廠獵積廠襯 (選築範築構遞蓋醖選淵, 3.63 ~ 5.39) 更多	-	2021-07-23